Literature DB >> 23669227

Benefits and adverse events in younger versus older patients receiving neoadjuvant chemotherapy for osteosarcoma: findings from a meta-analysis.

Marnie Collins1, Miriam Wilhelm, Rachel Conyers, Alan Herschtal, Jeremy Whelan, Stefan Bielack, Leo Kager, Thomas Kühne, Matthew Sydes, Hans Gelderblom, Stefano Ferrari, Piero Picci, Sigbjørn Smeland, Mikael Eriksson, Antonio Sérgio Petrilli, Archie Bleyer, David M Thomas.   

Abstract

PURPOSE: The LIVESTRONG Young Adult Alliance has conducted a meta-analysis of individual patient data from prospective neoadjuvant chemotherapy osteosarcoma studies and registries to examine the relationships of sex, age, and toxicity on survival. PATIENTS AND METHODS: Suitable data sets were identified by a survey of published data reported in PubMed. The final pooled data set comprised 4,838 patients from five international cooperative groups.
RESULTS: After accounting for important variables known at study entry such as tumor location and histology, females experienced higher overall survival rates than males (P = .005) and children fared better than adolescents and adults (P = .002). Multivariate landmark analysis following surgery indicated that a higher rate of chemotherapy-induced tumor necrosis was associated with longer survival (P < .001), as was female sex (P = .004) and the incidence of grade 3 or 4 mucositis (P = .03). Age group was not statistically significant in this landmark analysis (P = .12). Females reported higher rates of grade 3 or 4 thrombocytopenia relative to males (P < .001). Children reported the highest rates of grade 3 or 4 neutropenia (P < .001) and thrombocytopenia (P < .001). The achievement of good tumor necrosis was higher for females than for males (P = .002) and for children than for adults (P < .001).
CONCLUSION: These results suggest fundamental differences in the way chemotherapy is handled by females compared with males and by children compared with older populations. These differences may influence survival in a disease in which chemotherapy is critical to overall outcomes.

Entities:  

Mesh:

Year:  2013        PMID: 23669227     DOI: 10.1200/JCO.2012.43.8598

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  61 in total

1.  Clinical Genomic Sequencing of Pediatric and Adult Osteosarcoma Reveals Distinct Molecular Subsets with Potentially Targetable Alterations.

Authors:  Yoshiyuki Suehara; Deepu Alex; Anita Bowman; Sumit Middha; Ahmet Zehir; Debyani Chakravarty; Lu Wang; George Jour; Khedoudja Nafa; Takuo Hayashi; Achim A Jungbluth; Denise Frosina; Emily Slotkin; Neerav Shukla; Paul Meyers; John H Healey; Meera Hameed; Marc Ladanyi
Journal:  Clin Cancer Res       Date:  2019-06-07       Impact factor: 12.531

2.  Downregulation of Semaphorin-3F is associated with poor prognostic significance in osteosarcoma patients.

Authors:  Ming-Han Liu; Wen-Juan Fu; You-Hong Cui; Qiao-Nan Guo; Yue Zhou
Journal:  Am J Cancer Res       Date:  2016-10-01       Impact factor: 6.166

3.  Prediction of response to neoadjuvant chemotherapy in osteosarcoma using dual-phase (18)F-FDG PET/CT.

Authors:  Byung Hyun Byun; Sung Hoon Kim; Sang Moo Lim; Ilhan Lim; Chang-Bae Kong; Won Seok Song; Wan Hyeong Cho; Dae-Geun Jeon; Soo-Yong Lee; Jae-Soo Koh; Soo Kyo Chung
Journal:  Eur Radiol       Date:  2015-02-14       Impact factor: 5.315

4.  CD8+/FOXP3+-ratio in osteosarcoma microenvironment separates survivors from non-survivors: a multicenter validated retrospective study.

Authors:  Benedikt Fritzsching; Joerg Fellenberg; Linda Moskovszky; Zoltan Sápi; Tibor Krenacs; Isidro Machado; Johannes Poeschl; Burkhard Lehner; Miklos Szendrõi; Antonio Llombart Bosch; Ludger Bernd; Monika Csóka; Gunhild Mechtersheimer; Volker Ewerbeck; Ralf Kinscherf; Pierre Kunz
Journal:  Oncoimmunology       Date:  2015-04-02       Impact factor: 8.110

5.  Diagnostic assessment of osteosarcoma chemoresistance based on Virtual Clinical Trials.

Authors:  K A Rejniak; M C Lloyd; D R Reed; M M Bui
Journal:  Med Hypotheses       Date:  2015-06-24       Impact factor: 1.538

6.  Overexpression of CD155 relates to metastasis and invasion in osteosarcoma.

Authors:  Baobiao Zhuo; Yuan Li; Feng Gu; Zhengwei Li; Qingzeng Sun; Yingchun Shi; Yang Shen; Fengfei Zhang; Rong Wang; Xiaodong Wang
Journal:  Oncol Lett       Date:  2018-03-09       Impact factor: 2.967

7.  GFRA1 promotes cisplatin-induced chemoresistance in osteosarcoma by inducing autophagy.

Authors:  Mihwa Kim; Ji-Yeon Jung; Seungho Choi; Hyunseung Lee; Liza D Morales; Jeong-Tae Koh; Sun Hun Kim; Yoo-Duk Choi; Chan Choi; Thomas J Slaga; Won Jae Kim; Dae Joon Kim
Journal:  Autophagy       Date:  2016-10-18       Impact factor: 16.016

8.  Age-related toxicity in patients with rhabdomyosarcoma: a report from the children's oncology group.

Authors:  Sadaf Altaf; Felicity Enders; Elizabeth Lyden; Sarah S Donaldson; David Rodeberg; Carola Arndt
Journal:  J Pediatr Hematol Oncol       Date:  2014-11       Impact factor: 1.289

Review 9.  Translational biology of osteosarcoma.

Authors:  Maya Kansara; Michele W Teng; Mark J Smyth; David M Thomas
Journal:  Nat Rev Cancer       Date:  2014-10-16       Impact factor: 60.716

10.  Elevated ASCL2 expression is associated with metastasis of osteosarcoma and predicts poor prognosis of the patients.

Authors:  Ming-Han Liu; You-Hong Cui; Qiao-Nan Guo; Yue Zhou
Journal:  Am J Cancer Res       Date:  2016-06-01       Impact factor: 6.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.